Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2021-12-03 Purchase | 2021-12-06 8:34 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 30,000 | $14.43 | $432,876 | 571,376 (Indirect Direct) | View |
| 2021-08-16 Sale | 2021-08-17 6:20 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 9,364 | $26.34 | $246,659 | 541,376 (Indirect Direct) | View |
| 2021-07-28 Sale | 2021-07-30 8:57 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 54,332 | $30.06 | $1,632,960 | 234,078 (Indirect Direct) | View |
| 2021-07-26 Sale | 2021-07-28 9:48 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 55,382 | $29.72 | $1,645,953 | 610,021 (Indirect Direct) | View |
| 2021-04-05 Sale | 2021-04-06 7:41 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 2 | $28.28 | $57 | 665,403 (Indirect Direct) | View |
| 2021-03-04 Sale | 2021-03-05 8:10 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 33,119 | $25.43 | $842,216 | 665,405 (Indirect Direct) | View |
| 2021-02-01 Sale | 2021-02-03 8:13 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 33,119 | $25.95 | $859,438 | 686,619 (Indirect Direct) | View |
| 2020-12-30 Sale | 2021-01-04 8:01 pm | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 33,119 | $27.82 | $921,212 | 719,738 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-03-15 Tax Withholding | 2022-03-17 5:50 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Rankin Aubrey Director | 1,372 | $15.79 | 570,004 (Direct) | View |
| 2021-08-15 Tax Withholding | 2021-08-17 6:20 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 4,949 | $26.02 | 541,376 (Direct) | View |
| 2021-02-02 Option Award | 2021-02-04 9:16 pm | N/A 2031-02-01 | Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech | 33,445 | $0 | 720,064 (Direct) | View |